COMMANDER HF - Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Purpose: Assessment of safety and efficacy of rivaroxaban vs placebo in HF patients with significant coronary artery disease following an episode of decompensated heart failure.

Trial Design: N = 5022. parallel, randomized 1:1, double-blinded, multicenter; standard of care + either 2.5 mg of rivaroxaban twice daily vs placebo; median 21.1-month follow-up.

Primary Endpoints: Composite of heart attack, stroke or any cause death. Serious or fatal bleeding.

Secondary: CV death or re-hospitalization for HF.

	rivaroxaban	placebo	P value
Composite of MI, stroke or any cause death (efficacy)	25%	26.2%	0.27
Serious or fatal bleeding (safety)	18 patients	23 patients	0.48
All-cause mortality	21.8%	22.1%	

Results: The primary endpoint rate was not significantly lower with rivaroxaban compared to placebo in this patient population.

Presented by: Faiez ZANNAD, ESC 2018 Munich, Germany